Structure-function relationships of complement receptor type 1

Immunological Reviews

Volumn 180, Issue , 2001, Pages 112-122

  Krych Goldberg, Malgorzata ^a   Atkinson, John P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4B; DECAY ACCELERATING FACTOR;

AMINO ACID SEQUENCE; ANTIGEN ANTIBODY COMPLEX; COMPLEMENT ACTIVATION; COMPLEMENT FIXATION; COMPLEMENT SYSTEM; ERYTHROCYTE; HUMAN; HYDROPHOBICITY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BLOOD CELLS; COMPLEMENT ACTIVATION; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT C3B; COMPLEMENT C4B; DRUG DESIGN; HUMANS; MAMMALS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PEPTIDE FRAGMENTS; POLYMORPHISM, GENETIC; PRIMATES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, COMPLEMENT 3B; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035018479     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2001.1800110.x     Document Type: Review

References (94)

1. 1. Perkins SJ, Harris PI, Sim PB, Chapman D. A study of the structure of human complement component Factor H by fourier transform infrared spectroscopy and secondary structure averaging methods. Biochemistry 1988;27:4004-4012.
2. 2. Barlow PN, et al. Solution structure of the fifth repeat of Factor H: a second example of the complement control protein module. Biochemistry 1992;31:3626-3634.
3. 3. Barlow PN, et al. Solution structure of a pair of complement modules by nuclear magnetic resonance. J Mol Biol 1993;232:268-284.
4. 4. Wiles AP, Shaw G, Bright J, Perczel A, Campbell ID, Barlow PN. NMR studies of a viral protein that mimics the regulators of complement activation. J Mol Biol 1997;272:253-265.
5. 5. Klickstein LB, Wong WW, Smith JA, Weis JH, Wilson JG, Fearon DT. Human C3b/C4b receptor (CR1): demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristic of C3b/C4b binding proteins. J Exp Med 1987;165:1095-1112.
6. 6. Hourcade D, Miesner DR, Atkinson JP, Holers VM. Identification of an alternative polyadenylation site in the human C3b/ C4b receptor (CR1) transcriptional unit and prediction of a secreted form of CR1. J Exp Med 1988;168:1255-1270.
7. 7. Dykman TR, Cole JL, Iida K, Atkinson JP. Polymorphism of the human erythrocyte's C3b/C4b receptor. Proc Natl Acad Sci USA 1983;80:1698-1702.
8. 8. Wong WW, Wilson JC, Fearon DT. Genetic regulation of a structural polymorphism of human C3b receptor. J Clin Invest 1983;72:680-685.
9. 9. Dykman TR, Hatch JA, Atkinson JP. Polymorphism of the human C3b/C4b receptor: Identification of a third allele and analysis of receptor phenotypes in families and patients with systemic lupus erythematosus. J Exp Med 1984;159:691-703.
10. 10. Dykman TR, Hatch JA, Aqua MS, Atkinson JP. Polymorphism of the C3b/C4b receptor: identification of a rare variant. J Immunol 1985;134:1787-1789.
11. 11. Wong WW, Farrell SA. Proposed structure of the F′ allotype of human CR1. Loss of a C3b binding site may be associated with altered function. J Immunol 1990;146:656-662.
12. 12. Wong WW, et al. Structure of the human CR1 gene. Molecular basis of the structural and quantitative polymorphisms and identification of a new CR1-like allele. J Exp Med 1989;169:847-863.
13. 13. Wong WW, et al. Analysis of multiple restriction fragment length polymorphisms of the gene for the human complement receptor type 1: duplication of genomic sequences occurs in association with a high molecular weight receptor allotype. J Exp Med 1986;164:1531-1546.
14. 14. Moulds JM, Nickells MW, Moulds JJ, Brown MC, Atkinson JP. The C3b/C4b receptor is recognized by Knops, McCoy, Swain-Langley and York blood group antisera. J Exp Med 1991;173:1159-1163.
15. 15. Rao N, Ferguson DJ, Lee S-F, Telen MJ. Identification of human erythrocyte blood group antigens on the C3b/C4b receptor. J Immunol 1991;146:3502-3507.
16. 16. Moulds JM, Moulds JJ, Brown M, Atkinson JP. Antiglobulin testing for CR1-related (Knops/McCoy/Swain-Langley/York) blood group antigens; negative and weak reactions are caused by variable expression of CR1. Vox Sang 1992;62:230-235.
17. 17. Moulds JM, et al. Reference typing report for complement receptor 1 (CR1). Exp Clin Immunogenet 1998;15:291-294.
18. 18. Moulds JM, et al. Identification of complement receptor one (CR1) polymorphisms in West Africa. Genes Immun (In press).
19. 19. Rowe JA, Moulds JM, Newbold CI, Miller LH, P, falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1. Nature 1997;388:292-295.
20. 20. Wilson JB, Murphy EE, Wong WW, Klickstein LB, Weis JH, Fearon DT. Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes. J Exp Med 1986;164:50-59.
21. 21. Herrera AH, Xiang L, Martin SG, Lewis JWJG. Analysis of complement receptor type 1 (CR1) expression on erythrocytes and of CR1 allelic markers in Caucasian and African American populations. Clin Immunol Immunopathol 1998;87:176-183.
22. 22. Xiang L, Rundles JR, Hamilton DR, Wilson JG. Quantitative alleles of CR1: coding sequence analysis and comparison of haplotypes in two ethnic groups. J Immunol 1999;163:4939-4945.
23. 23. Lublin DM, Griffith R, Atkinson JP. Influence of glycosylation on allelic and cell-specific M, variation, receptor processing, and ligand binding of the human complement C3b/C4b receptor (CR1). J Biol Chem 1986;261:5736-5744.
24. 24. Dykman TR, Cole JL, Iids K, Atkinson JP. Structural heterogeneity of the C3b/C4b receptor (CR1) on human peripheral blood cells. J Exp Med 1983;157:2160-2165.
25. 25. Fearon DT. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte and monocyte. J Exp Med 1980;152:20-30.
26. 26. Tedder TF, Fearon DT, Gartland GL, Cooper MD. Expression of C3b receptors on human B cells and myelomonocytic cells but not natural killer cells. J Immunol 1983;130:1668-1673.
27. 27. Fearon DT, Collins LA. Increased expression of C3b receptors on polymorphonuclear leukocytes induced by chemotactic factors and by purification procedures. J Immunol 1983;130:370-375.
28. 28. O'Shea JJ, Brown EJ, Seligmann BE, Metcalf JA, Frank MM, Gallin JI. Evidence for distinct intracellular pools of receptors of C3b and C3bi in human neutrophils. J Immunol 1985;134:2580-2587.
29. 29. Berger M, Wetzler EM, Welter E, Turner JR, Tartakoff AM. Intracellular sites for storage and recycling of C3b receptors in human neutrophils. Proc Natl Acad Sci USA 1991;88:3019-3023.
30. 30. Sengelov H, Kjeldsen L, Kroeze W, Berger M, Borregaard N. Secretory vesicles are the intracellular reservoir of complement receptor 1 in human neutrophils. J Immunol 1994;153:804-810.
31. 31. Kumar A, Wetzler E, Berger M. Isolation and characterization of complement receptor type 1 (CR1) storage vesides from human neutrophils using antibodies to the cytoplasmic tail of CR1. Blood 1997;89:4555-4565.
32. 32. Reynes M, et al. Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J Immunol 1985;135:2694-2687.
33. 33. Fischer E, Appay MD, Cook J, Kazatchkine MD. Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor. J Immunol 1986;136:1373-1377.
34. 34. Appay MD, Kazatchkine MD, Levi-Strauss M, Hinglais N, Bariety J. Expression of CR1 (CD35) mRNA in podocytes from adult and fetal human kidneys. Kidney Int 1990;38:289-293.
35. 35. Gasque P, et al. Identification and characterization of complement C3 receptors of human astrocytes. J Immunol 1996;156:2247-2255.
36. 36. Gasque P, Fontaine M, Morgan BP. Complement expression in human brain. J Immunol 1995;154:4726-4733.
37. 37. Yoon S, Fearon DT. Characterization of a soluble form of the C3b/C4b receptor (CR1) in humin plasma. J Immunol 1985;134:3332-3338.
38. 38. Pascual M, et al. Circulating soluble CR1 (CD35). Serum levels in diseases and evidence for its release by human leukocytes. J Immunol 1993;151:1702-1711.
39. 39. Danielsson C, Pascual M, French L, Steiger G, Schifferli JA. Soluble complement receptor type 1 (CD35) is released from leukocytes by surface cleavage. Eur J Immunol 1994;24:2725-2731.
40. 40. Hamer I, Paccaud JP, Belin D, Maeder C, Carpentier JL. Soluble form of complement C3b/C4b receptor (CR1) results from a proteolytic cleavage in the C-terminal region of CR1 transmembrane domain. Biochem J 1998;329:183-190.
41. 41. Cooper NR. Immune adherence by the fourth component of complement. Science 1969;165:396-398.
42. 42. Ross GD, Lambris JD, Cain JA, Newman SL. Generation of three different fragments of bound C3 with purified factor I or serum. Requirements for factor H vs CR1 cofactor activity. J Immunol 1982;129:2051-2060.
43. 43. Medof ME, Prince GM, Mold C. Release of soluble immune complexes from immune adherence receptors on human erythrocytes is mediated by C3b inactivator independently of Beta 1H and is accompanied by generation of C3c. Proc Natl Acad Sci USA 1982;79:5047-5051.
44. 44. Weis JJ, Tedder TF, Fearon DT. Identification of a 145,000 M, membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc Natl Acad Sci USA 1984;81:881-885.
45. 45. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996;271:348-350.
46. 2+ mobilization of chronic lymphocytic leukemia B cells. J Immunol 1991;146:1766-1772.
47. 47. Weiss L, Delfraissy JF, Vasquez A, Wallon C, Galanaud P, Kazatchkine MD. Monoclonal antibodies to the human C3b/C4b receptor (CR1) enhance specific B cell differentiation. J Immunol 1987;138:2988-2993.
48. 48. Wright SD, Silverstein SC. Tumor-promoting phorbol esters stimulate C3b and C3b′ receptor-mediated phagocytosis in cultured human monocytes. J Exp Med 1982;156:1149-1164.
49. 49. Fallman M, Andersson R, Andersson T. Signaling properties of CR3 (CD11b/CD18) and CR1 (CD35) in relation to phagocytosis of complement-opsonized particles. J Immunol 1993;151:330-338.
50. 50. Changelian PS, Fearon DT. Tissue-specific phosphorylation of complement receptors CR1 and CR2. J Exp Med 1986;163:101-115.
51. 51. Changelian PS, Jack RM, Collins LA, Fearon DT. PMA induces the ligand-independent internalization of CR1 on human neutrophils. J Immunol 1985;134:1851-1858.
52. 52. Bacle F, Haeffner-Cavaillon N, Laude M, Couturier C, Kazatchkine MD. Induction of IL-1 release through stimulation of the C3b/C4b complement receptor type one (CR1, CD35) on human monocytes. J Immunol 1990;144:147-152.
53. 53. Thieblemont N, Haeffner-Cavaillon N, Ledur A, L'Age-Stehr J, Ziegler-Hietbrock HW, Kazatchkine MD. CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4. Clin Exp Immunol 1993;92:106-113.
54. 54. Klickstein LB, Barbashov SF, Liu T, Jack RM, Nicholson-Weller A. Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity 1997;7:345-355.
55. 55. Ghiran I, Klickstein LB, Nicolson-Weller A. Mannan binding lectin binds complement receptor type 1 and augments IgG-scimulated phagocytosis. Immunopharmacology 2000;49:3.
56. 56. Jouvin MH, Rozenbaum W, Russo R, Kazatchkine MD. Decreased expression of the C3b/C4b complement receptor (CR1) in AIDS and AIDS-related syndromes correlates with clinical subpopulations of patients with HIV infection. AIDS 1987;1:89-94.
57. 57. Munson LG, Scott ME, Landay AL, Spear GT. Decreased levels of complement receptor 1 (CD35) on B lymphocytes in persons with HIV infection. Clin Immunol Immunopathol 1995;75:20-25.
58. 58. Atkinson JP. Immune complexes and the role of complement. In: Leroy EC, ed. Systemic vasculitis. New York: M. Dekker; 1992. p. 525-546.
59. 59. Kumar A, Sinha S, Khandekar PS, Banerjee K, Srivastava LM. Hind III genomic polymorphism of the C3b receptor (CR1) in patients with SLE: low erythrocyte CR1 expression is an acquired phenomenon. Immunol Cell Biol 1995;73:457-462.
60. 60. Cohen JH, Caudwell V, Levi-Strauss M, Bourgeois P, Kazatchkine MD. Genetic analysis of CR1 expression on erythrocytes of patients with systemic lupus erythematosus. Arthritis Rheum 1989;32:393-397.
61. 61. Lindahl G, Sjobring U, Johnsson E. Human complement regulators: a major target for pathogenic microorganisms. Curr Opin Immunol 2000;12:44-51.
62. 62. Rowe JA, et al. Mapping of the region of complement receptor (CR) 1 required for Plasmodium falciparum rosetting and demonstration of the importance of CR1 in rosetting in field isolates. J Immunol 2000;165:6341-6346.
63. 63. Nickells MW, Subramanian VB, Clemenza L, Atkinson JP. Identification of complement receptor type 1-related proteins on primate erythrocytes. J Immunol 1995;154:2829-2837.
64. 64. Birmingham DJ, Logar CM, Shen XP, Chen W. The baboon erythrocyte complement receptor is a glycophosphatidylinositol-linked protein encoded by a homologue of the human CR1-like genetic element. J Immunol 1996;157:2586-2892.
65. 65. Chen W, Logar CM, Shen XP, Birmingham DJ. The chimpanzee and cynomolgus monkey erythrocyte immune adherence receptors are encoded by CR1-like genes. Immunogenetics 2000;52:46-52.
66. 66. Subramanian VB, Clemenza L, Krych M, Atkinson JP. Substitution of two amino acids confers C3b binding to the C4b binding site of CR1 (CD35). Analysis based on ligand binding by chimpanzee erythrocyte complement receptor. J Immunol 1996;157:1242-1247.
67. 67. Manthei U, Nickells MW, Barnes SH, Ballard LL, Cui W, Atkinson JP. Identification of a C3b/C4b binding protein of rabbit platelets and leukocytes: a CR1-like candidate for the immune adherence receptor. J Immunol 1988;140:1228-1235.
68. 68. Taylor RP, Kujala G, Wilson K, Wright E, Harbin A. In vivo and in vitro studies of the binding of antibody/dsDNA immune complexes to rabbit and guinea pig platelets. J Immunol 1985;134:2550-2555.
69. 69. Kurtz CB, O'Toole E, Christensen SM, Weis JH. The murine complement receptor gene family. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. J Immunol 1990;144:3581-3591.
70. 70. Molina H, Wong W, Kinoshita T, Brenner C, Foley S, Holers VM. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med 1992;175:121-129.
71. 71. Kinoshita T, Takeda J, Hong K, Kozono H, Sakai H, Inoue K. Monoclonal antibodies to mouse complement receptor type 1 (CR1): their use in a distribution study showing that mouse erythiocytes and platelets are CR1 negative. J Immunol 1988;140:3066-3072.
72. 72. Hourcade D, Miesner DR, Bee C, Zeldes W, Atkinson JP. Duplication and divergence of the aminoterminal coding region of the complement receptor 1 (CR1) gene. J Biol Chem 1990;265:974-980.
73. 73. Clemenza L, Subramanian B, Hourcade D, Nickells M, Atkinson J. Primary sequence of baboon CR1 demonstrates concerted evolution within the CR1 gene. Mol Immunol 1997;34:297-304.
74. 74. Klickstein LB, Bartow TJ, Miletic V, Rabson LD, Smith JA, Fearon DT. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med 1988;168:1699-1717.
75. 2 chimeric complement inhibitor. J Exp Med 1991;174:1451-1460.
76. 76. Krych M, Hourcade D, Atkinson JP. Sites within the complement C3b/C4b receptor important for the specificity of ligand binding. Proc Natl Acad Sci USA 1991;88:4353-4357.
77. 77. Krych M, Hauhart R, Atkinson JP. Structure-function analysis of the active sites of complement receptor type 1. J Biol Chem 1998;273:8623-8629.
78. 78. Krych-Goldberg M, et al. Decay accelerating activity of complement receptor type 1 (CD35). J Biol Chem 1999;274:31160-31168.
79. 79. Krych M, Clemenza L, Howdeshell D, Hauhart R, Hourcade D, Atkinson JP. Analysis of the functional domains of complement receptor type 1 (C3b/C4b receptor; CD35) by substitution mutagenesis. J Biol Chem 1994;269:13273-13278.
80. 80. Taniguchi-Sidle A, Isenman DE. Interactions of human complement component C3 with factor B and with complement receptors type 1 (CR1, CD35) and type 3 (CR3, CD11b/CD18) involve an acidic sequence at the N-terminus of C3 α′-chain. J Immunol 1994;153:5285-5302.
81. 81. Villoutreix BO, Hardig Y, Wallqvist A, Covell DG, Garcia de Frutos P, Dahlback B. Structural investigation of C4b-binding protein by molecular modeling: localization of putative binding sites. Proteins 1998;31:391-405.
82. 82. Brodbeck WG, Kuttner-Kondo L, Mold C, Medof ME. Structure/function studies of human decay-accelerating factor. Immunology 2000;101:104-111.
83. 83. Krych-Goldberg M, Hauhart R, Blackmer D, Atkinson JP. Structural requirements for decay accelerating activity (DAA) in complement receptor 1 (CR1; CD35). Immunopharmacology 2000;49:62.
84. 84. Kinoshita T, Rosenfeld SI, Nussenzweig V. A high m.w. form of decay-accelerating factor (DAF-2) exhibits size abnormalities in paroxysmal nocturnal hemoglobinuria erythrocytes. J Immunol 1987;138:2994-2998.
85. 86. Nickells MW, Alvarez JI, Lublin DM, Atkinson JP. Characterization of DAF-2, a high molecular weight form of decay-accelerating factor (DAF; CD55), as a covalently cross-linked dimer of DAF-1. J Immunol 1994;152:676-685.
86. 86. Birmingham DJ, Shen SP, Hourcade D, Nickells MW, Atkinson JP. Primary sequence of an alternatively spliced form of CR1: a candidate for the 75,000 M, complement receptor expressed on chimpanzee erythrocytes. J Immunol 1994;153:691-700.
87. 87. Klickstein LB, Moore FD Jr, Atkinson JP. Therapeutic inhibition of complement activation with emphasis on drugs in clinical trials. In: Austen KF, Burakoff SJ, Strom TB, Rosen FS, eds. Therapeutic immunology, Malden (MA): Blackwell Science; 2000. p. 287-301.
88. 88. Perry GJ, Eisenberg PR, Zimmerman JI, Levin J. Phase I safety trial of soluble complement receptor type 1 (TP10) in acute myocardial infarction. J Am Coll Cardiol 1998;31:411A.
89. 89. Zimmerman JL, Dellinger RP, Straube RC, Levin JL, Phase I dial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care Med 2000;28:3149-3154.
90. 90. Zamora MR, et al. Complement inhibition attenuates human lung transplant reperfusion injury: a multicenter trial. Chest 1999;116:46S.
91. 91. Rittershaus CW, et al. Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules. J Biol Chem 1999;274:11237-11244.
92. 92. Craig ML, Bankovich AJ, McElhenny JL, Taylor RP. Clearance of anti-double-stranded DNA antibodies. Arthritis Rheum 2000;43:2265-2275.
93. 93. Morgan BP, Harris CL. Complement regulatory proteins. San Diego: Harcourt Brace & Company; 1999.
94. 94. Klickstein LB, Moulds JM. CR1. In: Morley BJ, Walport MJ, eds. The complement factsbook. San Diego: Academic Press; 2000, p. 136-145.